which Dr Coope and her colleagues based their statistics are not available and may, in fact, not differ markedly from the range of normal for their laboratory. For example, although they comment on raised levels of factor X, there is no significant difference in this parameter between their oestrogentreated and placebo groups. The thromboelastogram also showed no significant change. The clinical significance of their reported changes cannot, therefore, be defined.
The main indication for long-term oestrogen replacement therapy is to prevent certain menopausal-related conditions such as oesteoporosis. By following patients for more than one year one can frequently detect a biphasic effect in which, for example, disturbed carbohydrate balance is followed by normalization of tolerance.> The same may also be true of the coagulation mechanism. Thus von Kualla et al1 concluded that conjugated oestrogens produced a shift toward hypercoagulability as evidenced by a shift of the parameters of the thromboelastogram (in contrast to the findings of Dr Coope and her colleagues) and the detection of fibrin monomers. However, the latter test became positive more frequently after five than after 21 tablets. As far as I am aware, our study is the only long-term evaluation of the effect of natural oestrogens on coagulation.
Finally, it is commonly observed that certain women appear to have an increased sensitivity or idiosyncracy to oestrogens (including conjugated oestrogens) and react by developing (among other side effects) hyperglycaemia, ' hyperlipaemia,l and 'hypertension.6 It is therefore essential that greater consideration be given to individual response and that judgment should not be based solely on the reaction of a study group. Although formal long-term epidemiological surveys 
